The emphysema treatment segmentation by application delineates four primary categories that collectively define the market's revenue base. Bronchoscopic lung volume reduction (BLVR), employing minimally invasive valve or coil technologies, accounts for roughly 35 % of total spend, driven by its growing adoption in moderate‑to‑severe cases and reimbursement expansions. Surgical lung volume reduction (SLVR), encompassing traditional resection procedures, contributes about 25 % and remains significant in patients unsuitable for bronchoscopic approaches, reflecting higher procedural costs and longer hospital stays. Pharmacologic therapy, which includes long‑acting bronchodilators, anti‑inflammatory agents, and emerging biologics, represents approximately 30 % of the market, underpinned by chronic maintenance use and large patient populations. Finally, Pulmonary rehabilitation and supportive care captures the remaining 10 %, encompassing exercise training, education, and oxygen therapy that complement primary interventions. These application segments together form the market taxonomy, each influencing overall size through distinct cost structures, utilization rates, and payer dynamics.
